Immutep Announced Sunday, Phase 1 IMP761 Data Showing Statistically Significant, Exposure-Dependent T-Cell Immune Response Inhibition, Well Tolerated Across 7 Dose Levels With No Serious Adverse Events
Share
Why It Matters
Immutep's new medicine was tested safely on people. The drug worked as hoped and caused no big problems, which is good early progress.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.